CLOSE
Relax, we can help.
With so many features and functions, we fully understand that getting the software to do what you want can be daunting at times.
YIKES!
CHANGES SAVED
SESSION EXPIRED
We appreciate that your browser hung out with us for so long, but your session has expired! If you want to register, we need to refresh your connection. We limit session time to 30 minutes for your security and to free up unused registration slots for others.
SESSION EXPIRED
Your session on this page has expired. We expire your session to protect your information in case you sit on a page too long with no activity.
CREATE ACCOUNT
ACCOUNT TYPE:
Please enter your access code!
CREATE ACCOUNT
ACCOUNT TYPE:
CONTACT HOST
Primary Contact:
Heather Newton
Email | Alt Email | +15126195534

 
SHARE
Overview
Agenda
Speakers
CME/CE
Registration Fees
Accommodations
Transportation
Abstracts
SupportOpportunities
Download Documents
REGISTER NOW
THIS EVENT IS 100% FREE!

The United States and other countries around the world face a major public health concern with the current outbreak of COVID-19. At this time, the 13th International Congress on Myeloproliferative Neoplasms is still planned as scheduled for October 29-30, 2020 in New York City. We will continue to monitor and re-assess the status of our upcoming meeting and will post any updates to the Congress schedule here on the website.


Over the past two decades, the International Congress on Myeloproliferative Neoplasms has become the premier forum for discussion of the diagnosis and treatment of myeloproliferative neoplasms (MPNs), providing timely, relevant and meaningful information to attendees from around the world. 

The program for the 13th International MPN Congress will offer new information on the prognostic significance of leukocytosis in polycythemia vera, an approach to the differential diagnosis of hereditary erythrocytosis, an update on the clinical status of currently used MPN drugs, as well as new agents of potential value in the MPNs. The role of inflammation in conjunction with the biology and treatment of fatigue in MPN patients, and ruxolitinib-associated weight gain will be discussed.

Other presentations will include the new ELN recommendations for CML treatment, the hypereosinophilias, the status of diagnosis and therapy of mastocytosis, updates on CMMol and those clinical predictors helpful in MPN transplantation decisions. The differential diagnosis of thrombocytosis and the significance of clonal hematopoiesis, pediatric MPNs, and the prognostic role of NGS in MPNs will round out the program.

Congress attendees will have the opportunity to participate in a variety of educational formats including didactic sessions, case reviews, poster sessions and oral abstract presentations. Opportunity will exist for networking and one-on-one discussion with faculty. The format of the program is deliberately designed to be conducive to close interaction between the speakers and attendees. At least 300 hematologists/oncologists and other healthcare professionals are expected to attend this 1.5-day event, featuring a world class faculty and offering CME and CE credit for attendees.

Location
Address
Crowne Plaza Times Square
1605 Broadway
New York City, NY  USA
Register Now

REGISTER TODAY!

EARLY RATES available until September 1st!

SELECTION OPTIONS
US Dollar
 
registration fee
Physician
Physician
$ 249.00  

Registration fees include conference materials, admittance to all scientific sessions, processing of certificates of attendance or continuing medical education, and all event meals and functions as specified in the agenda.

 
PA / Nurse / Fellow / Resident / Other
PA / Nurse / Fellow / Resident / Other
$ 149.00  

Registration fees include conference materials, admittance to all scientific sessions, processing of certificates of attendance or continuing medical education, and all event meals and functions as specified in the agenda.

 
Exhibitor/Industry
Exhibitor/Industry
$ 299.00  

Registration fees include conference materials, admittance to all scientific sessions, processing of certificates of attendance or continuing medical education, and all event meals and functions as specified in the agenda.

 
 
sessions
Continental Breakfast (I)
Continental Breakfast (I)
 


 
General Session I
General Session I
 
  • Welcome and Introduction
  • Hereditary Erythrocytosis
  • Thrombocytosis: Benign and Malignant
  • Persistent Leukocytosis is Associated with PV Progression
 
General Session II
General Session II
 
  • JAK2V617F and Clonal Hematopoiesis
  • NGS in MPN Diagnosis and Treatment: Update
  • Events Leading to MPN Disease Progression 
 
Lunch Session
Lunch Session
 


 
General Session III
General Session III
 
  • Update on the Clinical Status of Commonly Used Drugs in Myelofibrosis
  • New Agents of Potential Value in the MPN
  • Update of Phase 3 Trials of Recombinant Interferon Alpha in PV
 
General Session IV
General Session IV
 
  • Update on Pediatric MPN
  • What's New in the Hypereosinophilic Syndrome?
  • Diagnostic Evaluation and Therapy in Mastocytosis: Status 2020
  • Abstract Presentations & Discussions
 
Welcome Reception and Poster Presentations
Welcome Reception and Poster Presentations
 


 
Continental Breakfast (II)
Continental Breakfast (II)
 


 
General Session V
General Session V
 
  • The Role of Inflammation in the MPN
  • Fatigue in MPN Patients: Biology and Treatment
  • Weight Gain and Ruxolitinib in Myelofibrosis
  • New ELN Recommendations for CML and Importance in Clinical Practice
 
General Session VI
General Session VI
 
  • Interferon Prolongs Myelofibrosis-free and Overall Survival in PV
  • Which Published Schema are Helpful in MPN Transplant Decisions?
  • Update on Chronic Myelomonocytic Leukemia
  • Limitations of Clinical Trials
  • Closing Remarks
 
POWERED BY